Rabbit Polyclonal CHST1 Antibody

+ +

•  

   
     All lanes : Anti-CHST1 Antibody (C-term) at 1:2000 dilution Lane 1: human brain lysates Lane 2: Hela whole cell lysates Lane 3: Jurkat whole cell lysates Lane 4: mouse brain lysates Lane 5: rat brain lysates Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG,  (H+L), Peroxidase conjugated at 1/10000 dilution Predicted band size : 47 kDa Blocking/Dilution buffer: 5% NFDM/TBST.    

•  

   
     P33059 staining CHST1 in Human skeletal muscle tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,  paraffin-embedded sections).  Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).  Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

**Background of CHST1 Antibody**

The CHST1 (Carbohydrate Sulfotransferase 1) antibody is a tool used to study the CHST1 protein, a member of the sulfotransferase family that catalyzes the transfer of sulfate groups to carbohydrate moieties. CHST1 specifically mediates the sulfation of chondroitin sulfate, a critical glycosaminoglycan (GAG) involved in extracellular matrix (ECM) remodeling, cell signaling, and tissue development. This enzyme plays a role in nervous system development, wound healing, and tumor progression by modulating sulfation patterns, which influence cell adhesion, migration, and interactions with growth factors.

CHST1 antibodies are typically developed as monoclonal or polyclonal reagents for applications like Western blotting, immunohistochemistry (IHC), or immunofluorescence (IF). They enable researchers to detect CHST1 expression, localization, and abundance in tissues or cell lines, particularly in studies exploring diseases linked to chondroitin sulfate dysregulation, such as cancer, fibrosis, or neurological disorders. For instance, elevated CHST1 levels have been observed in glioblastoma and colorectal cancer, correlating with aggressive tumor behavior.

Validation of CHST1 antibodies often includes knockout cell line controls to ensure specificity. Their utility extends to elucidating CHST1's functional interactions with ECM components, growth factor receptors (e.g., TGF-β), and integrins, offering insights into therapeutic targeting of sulfation-dependent pathways in disease.